Close Menu

NEW YORK (360Dx) – Bio-Techne announced after the close of the market on Monday that it has reached an agreement to acquire Exosome Diagnostics for up to $575 million.

Under the terms of the deal, expected to close in July or early August, Bio-Techne will pay $250 million in cash up front, and up to an additional $325 million contingent on the achievement of certain future milestones. The company said it will finance the deal through a combination of cash on hand and a revolving line of credit facility it anticipates obtaining prior to the closing of the deal.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.